医药板块爆发，医疗ETF（159828）涨超2%，创新药ETF国泰（517110）、创业板医药ETF国泰（159377）涨超1%

Group 1 - The pharmaceutical sector is experiencing a surge, with medical ETFs (159828) rising over 2%, and innovative drug ETFs (517110) and ChiNext medical ETFs (159377) increasing over 1% [1] - The National Healthcare Security Administration has initiated the deepening phase of centralized drug procurement, emphasizing principles such as "stabilizing clinical use, ensuring quality, preventing collusion, and countering internal competition" [1] - The 11th batch of centralized procurement rules has been significantly optimized, allowing medical institutions to select recognized brands and requiring lowest-priced companies to justify their pricing and commit to not pricing below cost [1] Group 2 - This adjustment aims to curb vicious price competition and shift the industry focus from "price wars" to "value wars," benefiting leading companies with stable production capabilities and strong cost control [1] - The National Healthcare Security Administration has conducted price governance for over 27,000 drug specifications, which is expected to further concentrate market share among high-quality leading enterprises [1] - The exploration of direct settlement of procurement and national negotiation drug consumables by the medical insurance fund aims to reduce the payment cycle for pharmaceutical companies from 6 months to under 30 days, significantly improving cash flow and overall operational efficiency in the industry [1]